H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Quantum-Si (QSI) to $5.50 from $4 and keeps a Buy rating on the shares. The company hosted an investor day to unveil its new and enhanced protein sequencing technology as well as discuss its go-to-market strategy, the analyst tells investors in a research note. The firm says Quantum-Si’s new sequencing platform “could be a game-changer.” Proteus could help to significantly deepen and broaden market penetration beyond academic institutions to government and pharma sectors, who may be able to utilize the technology for applications, such as translational medicine, drug discovery, and diagnostics, contends H.C. Wainwright.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on QSI:
- Quantum-Si and SkyWater Technology expand relationship to develop Proteus
- Quantum-Si price target lowered to $1 from $1.50 at Canaccord
- Quantum-Si Reports Q3 2024 Financial Results
- Quantum-Si says ‘ likely’ will not meet FY24 revenue view of $3.7M-$4.2M
- Quantum-Si reports Q3 EPS (18c), consensus (19c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
